Moderna is trading up 4.2% at $225.34 on October 14; coverage describes an intraday rebound but identifies no clear catalyst. - The recent rally has been linked to optimism around its personalized melanoma vaccine with Merck and anticipation of Phase 3 data at ESMO; this is prior context. - Citi’s October 14 Sell downgrade reportedly pressured shares in premarket trading, rather than explaining the subsequent rise. - Major indices and biotech were lower, offering no explanation for Moderna’s gain.